Bank Of Hawaii Regeneron Pharmaceuticals, Inc. Transaction History

Bank Of Hawaii

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 10, 2021	SELL	$478.3 - $607.98 $172,666 - $219,480	-361 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$544.75 - $658.21 $81,712 - $98,731	-150 Reduced 29.35%	361 $202,000
Q2 2020 Aug 14, 2020	SELL	$493.32 - $643.92 $333,484 - $435,289	-676 Reduced 56.95%	511 $319,000
Q1 2020 May 13, 2020	BUY	$336.18 - $494.43 $399,045 - $586,888	1,187 New	1,187 $580,000
Q2 2019 Aug 15, 2019	SELL	$299.6 - $414.82 $414,346 - $573,696	-1,383 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$372.08 - $439.57 $103,438 - $122,200	278 Added 25.16%	1,383 $568,000
Q4 2018 Feb 13, 2019	SELL	$335.82 - $403.04 $320,036 - $384,097	-953 Reduced 46.31%	1,105 $413,000
Q3 2018 Nov 09, 2018	BUY	$351.14 - $408.51 $116,929 - $136,033	333 Added 19.3%	2,058 $832,000
Q2 2018 Aug 06, 2018	BUY	$284.6 - $344.99 $58,343 - $70,722	205 Added 13.49%	1,725 $595,000
Q1 2018 May 04, 2018	BUY	$315.82 - $393.78 $480,046 - $598,545	1,520 New	1,520 $523,000

1,534

83.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.3B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Bank Of Hawaii, based on Form 13F filings with the SEC.

Stay updated on Bank Of Hawaii with notifications on news.